Skip to content

R&D at other companies

Amgen logo
AmgenAMGN
$1.72B+15.7%
3M logo
3MMMM
$308M+8.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$205M-0.5%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$15.33M+7.5%
Biogen logo
BiogenBIIB
$172.8M-3.2%
Glaukos logo
GlaukosGKOS
$2.5M-16.7%

Other financials

Income statement

See full
Revenue$448.5M+5.7%
Gross profit$237.6M+4.8%
Operating income$90.3M+5.1%
Net income$81.8M+14.8%
EPS (diluted)$1.58+20.6%

Balance sheet

See full
Cash & equivalents$800.9M+48.4%
Total debt$134.0M-6.8%
Total equity$2.1B+9.2%
Total assets$2.5B+7.0%

Cash flow

See full
Operating cash flow$151.4M+16.1%
CapEx$2.4M-30.1%
Free cash flow$149.0M+17.4%

Valuation

See full
Market cap$8.34B+39.3%
Enterprise value$7.67B+36.9%
P/E20.1×+2.1×
P/S4.2×+1.0×

Profitability

See full
Gross margin52.8%+0.2pp
Operating margin23%+1.4pp
Net margin20.7%+3.3pp
FCF margin31.9%+9.6pp

Returns & leverage

See full
Return on equity20.3%+2.7pp
Debt / equity0.1×0.0×
Current ratio7.4×+1.0×

Where this comes from

Reported directly by Cirrus Logic in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Cirrus Logic’s 10-K, filed May 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cirrus Logic's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cirrus Logic's R&D?
Cirrus Logic (CRUS) reported R&D of $107.49M in Q1 2026.
How has Cirrus Logic's R&D changed year-over-year?
Cirrus Logic's R&D increased by 3.9% year-over-year, from $103.42M to $107.49M.
What is the long-term trend for Cirrus Logic's R&D?
Over 4 years (2022 to 2026), Cirrus Logic's R&D has grown at a 1.7% compound annual growth rate (CAGR), from $406.31M to $433.95M.
What does R&D mean?
Spending on the creation and improvement of products and technologies.
How do you interpret R&D?
Higher spending indicates a commitment to future growth and innovation, though it reduces short-term profitability.
How does R&D compare across companies?
High in technology and pharmaceutical sectors; lower in mature, non-innovative industries.